Osteoclast differentiation and activation

被引：5187

作者：

Boyle, WJ ^{[2
]}

Simonet, WS

Lacey, DL

机构：

[1] Amgen Inc, Thousand Oaks, CA 91320 USA

[2] Prot Pathways Inc, Woodland Hills, CA 91367 USA

来源：

NATURE | 2003年 / 423卷 / 6937期

关键词：

D O I：

10.1038/nature01658

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Osteoclasts are specialized cells derived from the monocyte/macrophage haematopoietic lineage that develop and adhere to bone matrix, then secrete acid and lytic enzymes that degrade it in a specialized, extracellular compartment. Discovery of the RANK signalling pathway in the osteoclast has provided insight into the mechanisms of osteoclastogenesis and activation of bone resorption, and how hormonal signals impact bone structure and mass. Further study of this pathway is providing the molecular basis for developing therapeutics to treat osteoporosis and other diseases of bone loss.

引用

收藏

页码：337 / 342

页数：6

相关论文

共 77 条

[1] A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].

Anderson, DM ;

Maraskovsky, E ;

Billingsley, WL ;

Dougall, WC ;

Tometsko, ME ;

Roux, ER ;

Teepe, MC ;

DuBose, RF ;

Cosman, D ;

Galibert, L .

NATURE, 1997, 390 (6656) :175-179

[2] Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors [J].

Arai, F ;

Miyamoto, T ;

Ohneda, O ;

Inada, T ;

Sudo, T ;

Brasel, K ;

Miyata, T ;

Anderson, DM ;

Suda, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (12) :1741-1754

[3] A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function [J].

Armstrong, AP ;

Tometsko, ME ;

Glaccum, M ;

Sutherland, CL ;

Cosman, D ;

Dougall, WC .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (46) :44347-44356

[4] C-myc is required for osteoclast differentiation [J].

Battaglino, R ;

Kim, D ;

Fu, J ;

Vaage, B ;

Fu, XY ;

Stashenko, P .

JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (05) :763-773

[5] The effect of a single dose of osteoprotegerin in postmenopausal women [J].

Bekker, PJ ;

Holloway, D ;

Nakanishi, A ;

Arrighi, M ;

Leese, PT ;

Dunstan, CR .

JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (02) :348-360

[6] A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases [J].

Body, JJ ;

Greipp, P ;

Coleman, RE ;

Facon, T ;

Geurs, F ;

Fermand, JP ;

Harousseau, JL ;

Lipton, A ;

Mariette, X ;

Williams, CD ;

Nakanishi, A ;

Holloway, D ;

Martin, SW ;

Dunstan, CR ;

Bekker, PJ .

CANCER, 2003, 97 (03) :887-892

[7] osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].

Bucay, N ;

Sarosi, I ;

Dunstan, CR ;

Morony, S ;

Tarpley, J ;

Capparelli, C ;

Scully, S ;

Tan, HL ;

Xu, WL ;

Lacey, DL ;

Boyle, WJ ;

Simonet, WS .

GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268

[8] The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts [J].

Burgess, TL ;

Qian, YX ;

Kaufman, S ;

Ring, BD ;

Van, G ;

Capparelli, C ;

Kelley, M ;

Hsu, HL ;

Boyle, WJ ;

Dunstan, CR ;

Hu, S ;

Lacey, DL .

JOURNAL OF CELL BIOLOGY, 1999, 145 (03) :527-538

[9] Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFκB [J].

Cappellen, D ;

Luong-Nguyen, NH ;

Bongiovanni, S ;

Grenet, O ;

Wanke, C ;

Susa, M .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) :21971-21982

[10]

CHAGRAOUI H, IN PRESS BLOOD

← 1 2 3 4 5 6 7 8 →